Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Muscular Disease Therapies Show Efficacy In Various Studies

09/24/2021 | 01:44am EDT


© MT Newswires 2021
All news about ROCHE HOLDING AG
10/22Roche's implant for chronic eye disorder wins U.S. approval
RE
10/22ROCHE : eye implant wins FDA approval
RE
10/22ROCHE : FDA Approves Genentech's Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet..
BU
10/22ROCHE : FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovasc..
AQ
10/22PRESS RELEASE : FDA approves Roche's Susvimo, a -2-
DJ
10/22PRESS RELEASE : FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for..
DJ
10/22Roche Announces FDA Approves its Susvimo, Therapeutic Approach for Neovascular or Wet A..
CI
10/22Lymphoma Hub maintains its focus on raising the levels of global knowledge of lymphoma ..
AQ
10/22ROCHE : Wins US FDA Nod For VENTANA Test In Non-Small Cell Lung Cancer Patients
MT
10/22ROCHE : VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to ide..
AQ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 027 M 67 683 M 67 683 M
Net income 2021 15 089 M 16 465 M 16 465 M
Net cash 2021 4 790 M 5 227 M 5 227 M
P/E ratio 2021 19,8x
Yield 2021 2,64%
Capitalization 310 B 338 B 338 B
EV / Sales 2021 4,92x
EV / Sales 2022 4,76x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 355,80 CHF
Average target price 383,40 CHF
Spread / Average Target 7,76%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG15.15%337 974
JOHNSON & JOHNSON4.03%430 990
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979
MERCK & CO., INC.-0.79%205 421